Market Overview

$150+ Bn Computer-Aided Drug Discovery Services Market, 2018-2030

Share:

Dublin, Aug. 13, 2018 (GLOBE NEWSWIRE) -- The "Computer-Aided Drug Discovery Services Market, 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The early stages of research related to drug discovery, including the identification of a relevant biological target and a viable lead compound, play a crucial role in the overall success of a drug candidate in preclinical and clinical studies. It is also worth noting that the process of drug discovery is extremely demanding, both in terms of capital requirements and time. Moreover, there is always a high risk of failure associated with R&D programs and, considering the increasing regulatory stringency, the approval of new drugs has become significantly more difficult.

Given the increase in complexity of the drug discovery process, the overall R&D spending in the pharmaceutical/biotechnology sector has grown from around USD 128 billion in 2008 to USD 158 billion in 2017. As a result, the industry is currently under tremendous pressure not only to meet the expectations of a growing patient population, but also to identify ways to mitigate the risks associated with novel drug discovery programs to avoid failure.

Over the years, various computational tools and services have emerged, enabling the selection, modeling, analysis and optimization of potential lead candidates. The predictive power of computer-aided drug discovery (CADD) has proven to be extremely advantageous, allowing researchers to bypass the random screening of billions of molecules across hundreds of biological targets. As a result, players offering novel in silico drug discovery services, such as CADD, have now become an integral part of the pharmaceutical industry.

According to industry experts, almost 30% of the total cost and time invested in developing a new drug can be saved by utilizing such services. Owing to the significant cost benefits offered by such approaches, the adoption of CADD is anticipated to increase in the coming years. Furthermore, the growing number of drug discovery projects, coupled to their rapid progression through various stages of drug discovery, is expected to continue to create an increasing demand for computational services.

The Computer-Aided Drug Discovery Services Market, 2018-2030' report features an extensive study on the current landscape and the likely future potential of the players providing CADD services for drug discovery. The study provides an in-depth analysis, highlighting the capabilities of a diverse set of companies that offer such services across different stages of drug discovery, such as target identification, target validation, hit generation, hit-to-lead and lead optimization.

Amongst other elements, the report features:

  • An overview of the current market landscape, featuring a comprehensive list of over 120 players that offer CADD services, and detailed analysis based on a number of parameters, such as the location of headquarters, employee count, type of business model used (contract service providers, software/technology providers and consulting service providers), number of drug discovery step(s) for which the company offers CADD services (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of molecule(s) (biologics and small molecules), type of clientele (pharmaceutical/biotechnology companies and academic/research institutes), CADD approach adopted (structure-based drug design, ligand-based drug design and fragment-based drug design) and type of CADD service(s) offered (docking, molecular modeling and virtual screening etc.). In addition, the report features a year-wise analysis of the number of players that have been established over the past three decades.
  • An analysis of the most active regions based on the presence of CADD service providers; the report contains a schematic world map representation indicating the geographical location of key hubs with respect to outsourcing activity within this domain.
  • A logo landscape of the industry players engaged in this domain, distributed on the basis of the location of their respective headquarters and company size (very small-sized (50 employees) and large (>200 employees)).
  • Elaborate profiles of established players that offer a comprehensive range of CADD services and have received funding in the past two decades. Each profile provides an overview of the company, its financial performance (if available), funding information (if available), information on its CADD specific service(s) portfolio, and a comprehensive future outlook. In addition, each profile features a peer group-based benchmark comparison matrix for the players based on several parameters, such as the number of CADD service(s) offered, number of drug discovery step(s), type of molecule(s), type of clientele and experience of the company.
  • Tabulated profiles of emerging players (mid-sized companies or start-ups, established after 2012), featuring details on company headquarters, year of establishment, number of employees, key executives, funding information (if available), CADD service portfolio, CADD technology(if any), key developments related to CADD (if any) and business strategy.
  • An analysis of investments made in this domain; these include seed financing, venture capital financing, debt financing, equity crowdfunding and grants/awards received by the companies that are operating in this area.
  • An elaborate valuation analysis of companies involved in providing CADD services to the pharmaceutical/biotechnology industry. For this purpose, we have focused only on companies that have received funding in the past two decades, and built a multi-variable dependent model to estimate the current valuation of the aforementioned players.
  • A detailed analysis of the cost saving potential in the drug discovery process that can be brought about by the adoption of CADD.
  • A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery and are likely to impact early stage research over the coming years.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the CADD market over the coming decade. Based on several parameters, we have provided an informed estimate of the likely evolution of this market in the short to mid-term and long term, for the period 2018-2030.

Example Highlights

  • During our research, we identified over 120 players that are actively involved in providing a wide array of CADD services for drug discovery; lead optimization, hit-to-lead and lead generation are amongst the most popular drug discovery steps for which such services are offered. Around 15 companies offer end-to-end CADD services for drug discovery, starting from target identification to lead optimization. Examples of such one-stop-shops include (in alphabetical order)Allesh Biosciences Labs, CompChem Solutions, Evotec, Gfree Bio, GVK Biosciences, Quantitative Medicine, Sai Life Sciences, Shechter Computational Solutions and SilicsBio.
  • The current market is characterized by the presence of several established, as well as emerging players. Of these, 23% are large companies (more than 200 employees), 15% are mid-sized companies (50-200 employees), while 62% are small-sized players (less than 50 employees). Examples of established players with more than 25 years of experience in the pharmaceutical sector include (in alphabetical order) AMRI, Charles River Laboratories, ChemDiv, Evotec, RTI International, Schrdingerand XRQTC. Some of the new players that have recently entered this domain include (in alphabetical order) ChemBio Discovery Solutions, Discover Drugs, Fractal Therapeutics, Micar Innovation, Nostrum Biodiscovery and NovaData Solutions.
  • Around 80% of the CADD service providers are located in North America and Europe. It is also worth highlighting that there are several such players based in certain emerging regions within Asia Pacific, namely India and China. Examples of some of the large companies based in these locations include (in alphabetical order) ChemPartner, Excelra Knowledge Solutions, GVK Biosciences, Jubilant Biosys, Medicilon, Pharmaron, Sundia MediTech, Syngene, TCG Lifesciences, Viva Biotech and WuXi AppTec.
  • CADD solutions/services have been shown to significantly reduce the cost and time spent in early stage drug discovery. The computation approach is estimated to save as much as 30% of this cost and also enables researchers to expedite the overall process, saving a significant amount of time. By 2030, we anticipate net annual cost savings of over USD 9 billion to be brought about by the adoption of CADD in the drug discovery process.
  • Driven by the rising number of drugs in the discovery stage across various therapeutic areas, the market is expected to continue on its growth trajectory in the foreseen future. We expect the CADD market to grow at an annualized rate of ~12.4% between 2018 and 2030. In terms of therapeutic areas, oncological disorders (46%), neurological disorders (13%), immunological disorders (7%) and infectious diseases (6%) are expected to capture a significant fraction of the market by 2030.
  • Hit and lead related services are expected to possess the largest market share (over 85%) by 2030, followed by target-based services (which include target identification and target validation). Although, the current market is largely driven (over 70%) by small molecules, large molecule drugs are expected to make a relatively larger contributions in the foreseen future; upcoming CADD technologies are likely to provide the necessary impetus to fuel this growth.
  • In terms of geography, majority (~70%) of the market share is likely to be distributed between North America and Europe in 2030; other countries, such as China and Japan, are expected to grow at a relatively faster rate (~14%) in the coming decade.

Companies Mentioned

  • Aaranya Biosciences
  • Agilux Laboratories
  • Aisling Capital
  • A-Level Capital
  • Allesh Biosciences Labs
  • Almi Invest
  • AMRI
  • Andy Jennings Consulting
  • APEIRON Biologics
  • Aprecia Pharmaceuticals
  • Aptuit
  • Aquila BioMedical
  • Aragen Bioscience
  • Aris Pharmaceuticals
  • Asahi Kasei Pharma
  • Asclepia MedChem Solutions
  • AstraZeneca
  • ATHOS Service
  • Atlas Ventures
  • Aurora Fine Chemicals
  • Avistron Chemistry Services
  • Banco Santander
  • Bayer
  • BenevolentAI
  • BIANA
  • Bienta
  • BioAscent
  • BioDiscovery Group
  • BioDuro
  • BioGenerator
  • Biognos
  • Bionomics
  • BioNTech
  • BioSolveIT
  • Biotechnology Value Fund
  • Biovista
  • Blue Stream Laboratories
  • BOC Sciences
  • Brains On-Line
  • Broad Institute
  • CAChe Research
  • candidum
  • Carna Biosciences
  • Carrick Therapeutics
  • Cascade Investment
  • Center for the Development of Industrial Technology
  • Celgene
  • Celsis
  • Charles River Laboratories
  • ChemAxon
  • ChemBio Discovery Solutions
  • ChemDiv
  • ChemEnvision
  • Chemical Computing Group
  • ChemModeling
  • ChemoGenics BioPharma
  • Chemotargets
  • ChemPartner
  • China Canada Angels Alliance
  • ChrysCapital
  • CITIC M&A Fund
  • Clearlake Capital Group
  • Cloud Pharmaceuticals
  • CloudScientific
  • Colorado Computational
  • CompChem Solutions
  • Concept Life Science
  • Confluence Discovery Technologies
  • Conifer Point Pharmaceuticals
  • Creative Biolabs
  • Creative Biostructure
  • Crelux
  • Cresset
  • Crowdcube
  • CXR Biosciences
  • Cyclica
  • Cyprotex
  • Cystic Fibrosis Foundation
  • DCM Ventures
  • Deep Knowledge Ventures
  • Discover Drugs
  • DIVERCHIM
  • Eagle Pharmaceuticals
  • Edelris
  • Eli Lilly
  • EligoChem
  • Enamine Biology Services
  • Entelos
  • Epic Capital Management
  • Equinox Pharma
  • European Investment Fund
  • Euticals
  • Evotec
  • Excelra Knowledge Solutions
  • Exscientia
  • Fidelity Management & Research Company
  • Fidelta
  • Formex
  • Fractal Therapeutics
  • Galapagos
  • Genedata
  • Genentech
  • Genmab
  • Genomodel
  • Gfree Bio
  • GL Capital
  • GLSynthesis
  • Government of Singapore Investment
  • Greenpharma
  • GreenSky Capital
  • GTCR
  • GVK Biosciences
  • H3 Biomedicine
  • Harvard University
  • HH&E Ventures
  • IBM
  • Icagen
  • Innovate UK
  • Innovative Informatica Technologies
  • Inserm
  • Insilico Medicine
  • Inte:Ligand
  • Invus
  • IOTA Pharmaceuticals
  • Janssen Pharmaceuticals
  • Janus Henderson Investors
  • JPT Peptide Technologies
  • Jubilant Biosys
  • Juno Capital
  • KWS BioTest
  • Laxai Life Sciences
  • Lead Discovery Siena
  • Lead Molecular Design
  • LeadInvent Technologies
  • Legend Capital
  • Liatris Biosciences
  • Life Chemicals
  • Longbow Capital
  • LU Innovation, Lund University
  • Mascot Industries
  • Massachusetts Institute of Technology
  • Medicilon
  • Medisyn Technologies
  • Medit
  • Menarini Group
  • Merck
  • Micar Innovation
  • Michaelson Capital Partners
  • MIG Fonds
  • Mind the Byte
  • Molcode
  • Molecular Cornerstones
  • Molecular Discovery
  • Molecular Forecaster
  • Molsoft
  • Morphic Therapeutics
  • MPI Research
  • Nanosyn
  • National Institutes of Health
  • New England Discovery Partners
  • NiKem Research
  • Nimbus Therapeutics
  • Nodthera
  • Nostrum Biodiscovery
  • NovaData Solutions
  • NovaLead Pharma
  • NovAliX
  • NovaMechanics
  • Novartis
  • Novo Holdings
  • Novo Informatics
  • National Science Foundation
  • NuChem Therapeutics
  • Numerate
  • Oncotest
  • Ono Pharmaceutical
  • OTAVAchemicals
  • Oxford Bioscience Partners
  • Paraza Pharma
  • Pars Silico Bioinformatics Laboratory
  • PathoQuest
  • Peakdale Molecular
  • Petra Pharma
  • Pharma Inventor
  • Pharmacelera
  • Pharmaceutical Product Development
  • Pharmaron
  • Phoenix Equity Partners
  • Porton Pharma Solutions
  • Prestwick Chemical
  • Princeton BioMolecular Research
  • Profacgen
  • Prosarix
  • ProSciens
  • ProtoQSAR
  • Provid Pharmaceuticals
  • ProXyChem
  • Pyxis Discovery
  • Qsol Services India
  • Quantitative Medicine
  • RASA Life Science Informatics
  • Rebexsess Discovery Chemistry
  • Redmile Group
  • Redox Scientific
  • Resource & Environmental Consultants
  • Rosa
  • Rosetta Design Group
  • RTI International
  • Sai Life Sciences
  • Sandexis
  • Sanofi
  • SARomics Biostructures
  • Schrdinger
  • Scientific Analysis Laboratories
  • SciLifeLab
  • Selvita
  • Shechter Computational Solutions
  • Shire
  • SilcsBio
  • Simulations Plus
  • SmiLe Incubator
  • Spectris
  • Startup Health
  • Struengmann Family Office
  • Sundia MediTech
  • Sygnature Discovery
  • Syngene
  • Synsight
  • Taros Chemicals
  • TCG Lifesciences
  • The Carlyle Group
  • Leukemia and Lymphoma Society
  • Tri-Institutional Therapeutics Discovery Institute
  • True PharmaChem
  • Uni-Innovation Group
  • University College London
  • Van Drie Research
  • Victrix Computational and Medicinal Chemistry Consultancy
  • Vipergen
  • Virtua Drug
  • Viva Biotech
  • VLife Sciences Technologies
  • VLS 3D
  • Wellcome Trust
  • WIL Research Laboratories
  • Wildcard Pharmaceutical Consulting
  • Wilmington PharmaTech
  • WuXi AppTec
  • Wyss Institute
  • XRQTC
  • XtalPi
  • ZoBio
  • Zorilla Research

For more information about this report visit https://www.researchandmarkets.com/research/pxmwsb/150_bn?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery

Primary Logo

View Comments and Join the Discussion!
 

Latest Ratings

StockFirmActionPT
MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.